Biogen Inc. (BIIB) Earnings Call Transcript & Summary
February 13, 2024
Earnings Call Speaker Segments
Chuck Triano
executiveThanks, Katie. Hello everyone, and welcome to the Biogen call covering Q4 and the complete 2023 fiscal year. Prior to starting, please note that the earnings release, along with the associated financial tables — our GAAP financial measures and a reconciliation between GAAP and non-GAAP financial measures we'll be discussing today — can be found in the Investors section of biogen.com. Tables 1 and 2 contain our GAAP financials, while table 4 provides a reconciliation of our GAAP to non-GAAP financial results. In our view, non-GAAP financial results give a better picture of the business's ongoing economics and show how we run things internally. The slides for use during this call have also been posted on our website. I'd also like to note that forward-looking statements will be made, and these are based on what we currently expect. Such statements carry certain risks and uncertainties, and actual results could differ materially. For more detail, I suggest reviewing the risk factors covered in our SEC filings. Joining me today are our President and Chief Executive Officer, Chris Viehbacher; Dr. Priya Singhal, Head of Development; and our CFO, Mike McDonnell. Opening comments will come from Chris, Priya, and Mike, after which we'll go to the Q&A session. So that we can address as many questions as possible, please keep yourself to one question. With that said, I'll hand things over to Chris.
Chris Viehbacher
executiveThanks, Chuck. Morning, everyone. It was a year ago that I got the chance to walk through Biogen's quarterly results for the very first time. Back then, we laid out our goal of getting Biogen back to sustainable growth. Over the twelve months since, I believe we've come a long way, and it gives me tremendous pride and joy today to be able to put out earnings guidance — Mike will cover the specifics in more depth — indicating that we anticipate positive EPS growth. As I've mentioned many times, once Biogen is growing again, we truly believe it becomes a growth company for the foreseeable future; our current portfolio carries very little, arguably zero, exposure to the Inflation Reduction Act; no fresh patent expirations are really on the horizon beyond the ones already disclosed; and I believe we've put in place a range of additional steps that genuinely reposition Biogen for growth. So let me just run through a few of those. The first was really about refocusing this company on growth drivers, especially the launches of our new products. Last year Biogen had four new product launches stemming from FDA approvals. Among everyone in our industry, that ranks second highest. And as you know, that demanded a great deal of cultural change. Since its founding 45 years ago, the multiple sclerosis franchise has been the backbone of this company. Our employees care deeply about the physicians treating multiple sclerosis and the patients living with multiple sclerosis; and we remain a leader in that market; even so, that franchise confronts mounting competition, and we need to embrace new therapeutic categories and new businesses. So we've made a significant shift in resources and attention, above all toward LEQEMBI, ZURZUVAE, SKYCLARYS, and QALSODY. That said, we still have certain products under patent protection, again facing considerable competition. Take a product such as SPINRAZA — analyst forecasts had projected that it would decline. I'm especially proud of our teams for proving they could bring this product back to, in fact, even modest growth. Clearly, how a product is administered can serve as a competitive edge. So a pill, for instance, will be far more preferred than an infusion. But in some of these truly devastating diseases, what we observe is that efficacy remains the single most important factor; that's the reason SPINRAZA stays a leader in its segment; and Biogen excels at developing the medical evidence needed to back up the value proposition of its products. When I first joined this company, a lot of you pointed out that while our product lineup was mature, our cost structure ranked among the highest in the sector—and we moved to fix that. But it wasn't only about cutting expenses. Our aim was to rebuild the business from the ground up; we were changing where we put our attention, moving into new therapeutic areas, and we had to consider our capabilities, along with how nimble the organization could be and how many management layers existed. So we launched a fit-for-growth reengineering initiative. To date, we've secured $200 million in savings, and we expect to capture roughly half of the 800 million in net savings by the close of 2024. Naturally, that corresponds to $1 billion in gross savings; after that, we turned our attention to research and development. Biogen is a truly fascinating organization. Every disease Biogen pursues is genuinely devastating, and we go after—and there's considerable pride in the fact that we seek solutions for illnesses nobody else is tackling. Naturally, though, doing that makes you a pioneer. You're a pioneer, since frequently we don't truly grasp the fundamental disease biology behind these conditions, which means we assume substantial risk, and such trials can be exceedingly costly. Still, our world does need a company like Biogen, so our goal has been to concentrate research and development spending on the products capable of delivering the biggest impact. Naturally, we must handle portfolio risk. Biogen has to remain a company that grows sustainably and appeals to investors. We require capital to invest in fresh projects; thus, I believe that with Priya's assistance, we've managed to adopt a highly disciplined, objective perspective on the pipeline. We have four data readouts scheduled this year, once more on critically important illnesses, and Priya will cover that in greater detail. As we move into the following year, we'll be examining how to strengthen that pipeline. How should we reconsider our research efforts? Science has evolved considerably, yet we haven't necessarily made that sort of change at Biogen; therefore, I believe research and development matters enormously to Biogen and will keep being a growth source going forward. Now, when we consider what actually fuels growth, obviously we have LEQEMBI; and I'll remind everyone that, once again, we're pioneering not only in science but also in commercial terms. One intriguing aspect of this disease is that, regarding the product's efficacy, in many instances we examine a product's characteristics, but in truth, when discussing efficacy, what you're really asking is whether you're treating the right patient? For many years, actually, the field poured money into treatments that couldn't show any benefit for Alzheimer's disease, and that came with a couple of big issues. First, not enough of the drug could cross the blood-brain barrier, and second, we were treating the wrong patients. Clarity was the initial trial that truly made a convincing case for how much lowering plaque matters and how that affects cognition. That said, we're aware of certain findings we presented at CTAD suggesting that the sooner you intervene, the better your odds of demonstrating even stronger efficacy, since our real goal is protecting neurons or building conditions in which damaged neurons are able to bounce back. That's why we've put substantial resources into our AHEAD study, which examines presymptomatic patients. We're also putting money into what occurs once plaque is cleared and into looking at maintenance. We're working to make things easier on patients through a subcutaneous formulation. So this — the pioneering work goes on. And that pioneering work is also happening in the marketplace. Alzheimer's patients aren't in the system right now, and they're entering it. So at present we have roughly 2,000 patients receiving therapy. Now, as companies, we lack direct access to patient registries. You're all familiar with the CMS registry, but a handful of other registries exist too, such as ALZ-NET, for instance.
Chris Viehbacher
executiveAnd we've observed that a number of analysts have managed to get their hands on that data. One analyst report mentioned 3,300 patients on the registry. The most recent information we have — and once again, this isn't flawless information — but we have an indication that roughly 3,800 patients were on the registry as of last week. When you consider that, it implies we're adding somewhere around 260, 265 patients each week during the month of January; and from what we can determine, that represents roughly a 56% increase compared with what we saw in December. So it's clear that demand exists for the product. IDNs are clearly moving forward on creating the pathways for care and the protocols for treatment that will make access better. Positive P&T committee decisions have gone to 70 of the top 100 IDNs. By this point, orders for LEQEMBI have actually been placed by 80% of those. Yet when we talk with the people doing the PET scans, the MRIs, and those selling the blood diagnostics, rising activity and volume get reported by all of them. And so — as you saw in Eisai's results, their conviction is that for each patient on treatment, at least three or four times as many are actually sitting in waiting rooms. So very solid progress is, we do believe, being made by us. We feel the go-to-market approach has now been proven. With sufficient IDNs now having reimbursement plus care pathways established, we think the moment has arrived to step up our promotional efforts in the market. Accordingly, as Eisai made public, our total U.S. field force is going to grow by roughly 30%; and per what both sides settled on during the prior year, once that go-to-market approach was truly proven, the time had come for people at Biogen to begin calling on physicians as well; and naturally, we've witnessed the Japanese launch. I attended that launch meeting, and everyone at Biogen takes great pride in collaborating with our Eisai colleagues on bringing this to market in Japan. We've also gotten the green light for LEQEMBI in China, and that market rollout is set to begin toward the end of this year. So in every market where we're tracking LEQEMBI, the momentum is clearly building. As we've mentioned previously, this particular rollout is unlike anything we've done before; our consistent message to investors has been that adoption would build up gradually over time, and that's exactly the pattern emerging. Our confidence in LEQEMBI's significance over the long haul remains intact, for both the patients who need it and the numbers we report. Turning to SKYCLARYS, the U.S. launch figures are out there, with roughly 1,000 patients currently receiving treatment. We still don't have an approval for the pediatric population. The addressable group is roughly 4,500 people, meaning in around half a year since launch we've reached just over 20% of those receiving treatment. Launching drugs for rare conditions involves a tremendous amount of intricacy, and that's an area where Biogen is exceptionally capable. Dealing with specialty pharmacy and reimbursement brings no shortage of logistical difficulties. That's the reason we've demonstrated an ability to reduce the interval between the start form and shipment by 45%; about two-thirds of reimbursement coverage is available. And of course, patients and their doctors need substantial assistance. So we have patient services and family access managers who help patients and physicians navigate the care pathways. One pattern we've noticed with SPINRAZA: about a third of its revenue is generated in the U.S., with the remaining two-thirds coming from outside the U.S., and we expect SKYCLARYS to follow a similar model. As of last night, we shared news that the European Commission has granted formal approval for SKYCLARYS. We currently operate an expanded access program in several European nations, and we're setting up similar programs elsewhere, including in countries beyond the U.S. We're pursuing a global filing strategy so that all patients living with Friedreich's Ataxia have the chance to benefit from SKYCLARYS. On top of that, we're actively conducting the studies required to secure the indication for pediatric patients under 16. Turning to ZURZUVAE and postpartum depression — the unmet need here is enormous, and media interest has been tremendous. Our discussion covers maternal health as well as mental health, both of which rank among the major trends shaping society right now. Seeking care and actually receiving it has frequently proven hard for mothers; roughly 80,000 women receive a diagnosis annually, though the true occurrence is thought to far surpass half a million. That leaves a tremendous amount of effort needed to genuinely reach women dealing with postpartum depression. The early launch signals, I should note, are considerably better than what we anticipated and look quite encouraging — however, we're only looking at six weeks' worth of information. From my perspective, we'd like additional evidence before drawing any definitive judgments, though all of the signals we're receiving look very encouraging. Initially, our plan was to aim this offering at major depressive disorder, and then we shifted focus toward postpartum depression, which required us to revisit and renegotiate our agreements with payers. I want to express real gratitude toward the payers, since they've been covering prescriptions despite the fact that our contracting isn't fully settled yet, and my sense is that this is boosting demand as well. Given that, I'll hand things to Priya, because I believe what we increasingly want to begin discussing is both the products we're selling and the fresh optimism for patients emerging from our pipeline. So, Priya, over to you.
Priya Singhal
executiveThanks, Chris. Like we talked about before, we've been concentrating on examining and ranking our development pipeline, keeping a sharp focus on boosting the odds of success and raising potential returns on investment, as Chris pointed out. The aim all along was to concentrate our pipeline so it better reflects a balance of risk and reward — one we think could assist Biogen in reaching its objective of delivering sustainable growth. That work led to several programs being discontinued during the past year, particularly in areas where we saw substantial hurdles in regulatory development or commercialization. We also pointed to areas where our expertise runs deep and pipeline programs looked promising, which meant they deserved an invest-to-win strategy. Alzheimer's disease is one of those areas, where our pipeline leads the industry, and we do anticipate continuing to invest so we can broaden that leadership. This begins with capitalizing on our opportunity with LEQEMBI. Our top priority is to keep collaborating with Eisai to help make sure LEQEMBI reaches patients around the world who suffer from early Alzheimer's disease. Now that approvals have come through in the U.S., Japan and China, with filings under review right now in 14 additional markets, we think we're well along the path toward that objective. Next comes generating further treatment choices for patients. Data shown at CTAD last year regarding LEQEMBI indicates continued benefit tied to treatment extending out to 24-months, plus that treating earlier in the disease course produced a greater impact on clinical outcome; because of that, we're collaborating with Eisai to submit a filing for maintenance dosing with IV LEQEMBI or treatment every four-week, and we're also assessing LEQEMBI administration in preclinical AD, as Chris brought up, in the AHEAD 3 to 45 trial, which happens before symptoms begin. Eisai additionally intends to submit a filing for a subcutaneous version of LEQEMBI by the end of March. Past LEQEMBI, Biogen is also moving forward pipeline programs that target tau. We think tau stands for the next frontier in Alzheimer's therapeutics, and we're striving to back the development of diagnostic tests and pathways. Our ASO targeting tau, BIIB080, stands for a new mechanism for targeting tau that's distinct from earlier antibody attempt. In the Phase 1b study, we observed a convergence of target engagement, reduction in tau pathology in the brain, and improvement in exploratory measures of clinical outcome. These results leave us very encouraged, and we're presently evaluating BIIB080 in the Phase 2 CELIA study; we also have BIIB113 of Phase 1 small molecule aiming to cut down the aggregation of tau. Crucially, Jane and the research organization is likewise focused on what lies ahead for Alzheimer's treatments and is pursuing a multimodality approach to assess a number of other potential targets implicated in Alzheimer's disease biology. Turning past Alzheimer's disease, Biogen has a chance to broaden our expanding rare disease portfolio; we regard rare disease expertise as a core competency here at Biogen. I'll now turn to BIIB121 in Angelman's syndrome. Angelman syndrome is an uncommon inherited neurodevelopmental condition that affects roughly 1 out of every 15,000 births globally. Diagnosis typically happens during early childhood, and the disorder presents with things like profound delays in development, difficulty speaking, issues with coordination and balance, and it may also include seizures. Although no treatment specifically for this condition has received approval, people who have Angelman syndrome usually end up with a life expectancy close to normal. That said, they typically need round-the-clock care and cannot live on their own. Under typical circumstances, within neurons the paternal copy of the UBE3A gene gets silenced, so only the maternal copy is expressed; with Angelman syndrome, the maternal copy is missing or switched off because of a genetic mutation, which results in no UBE3A gene expression and harm to synaptic connections along with brain network activity; this shows up as a rise in slow, low brainwaves, also known as delta waves. The goal of BIIB121 is to lift that silencing from the paternal copy so that UBE3A gene expression can be restored. The HALOS 1 study is built as an open-label, multiple ascending dose trial spanning different age groups and dose levels to evaluate safety and tolerability, but notably, it also incorporates clinical measures we can apply toward judging therapeutic potential. That covers objective EEG testing, plus clinical evaluations looking at various domains of Angelman syndrome, including cognitive function alongside gross and fine motor abilities. Enrollment for the multiple ascending dose portion of the HALOS Study is now complete, and Ionis shared some promising early interim data last year. On the whole, safety and tolerability back continued dosing in the long-term extension, with no worrying safety patterns seen so far. The EEG findings hinted at early trends toward less slow delta wave activity relative to baseline; and clinician-rated clinical endpoints indicate that most participants showed some degree of gain in overall functioning. All told, these early trends leave us encouraged, and we look forward to sharing a fuller topline readout from the study, anticipated around the middle of the year. Once we've reviewed those results, Biogen will be able to decide whether to opt in and run a pivotal study. Turning to lupus, that's another condition where medical need remains substantially unmet. Right now we have two Phase 3 assets for Systemic Lupus Erythematosus, or SLE. The first is dapirolizumab pegol, which we're developing alongside UCB, and we anticipate a topline readout from the Phase 3 study around midyear this year. Should it be positive, we expect to run a second Phase 3 study. The second is litifilimab, our anti-BDCA2 antibody that was developed internally at Biogen; at present we have two ongoing Phase 3 trials of litifilimab in SLE. These trials are actively enrolling and use a 52-week primary endpoint. Litifilimab could also become a first-in-class biologic for Cutaneous Lupus Erythematosus, or CLE, a skin-related autoimmune disease that may come with severe scarring and dyspigmentation and can be separate from SLE. Like I've mentioned before, our attention has been on examining the pipeline so we can pinpoint and rank the fields where we think we possess adequate know-how and scientific certainty to bring patients meaningful new therapies. That first pass is now finished, but the effort keeps evolving, and we're dedicated to keeping ourselves answerable for hunting down scientific insights efficiently and for growing the pipeline in a way we see as having the proper balance of risk and reward. We're eager about 4 significant near-term readouts during this year, yet our sights stay on spotting further near-term chances, along with ongoing growth past neuroscience. Working together with Jane and research organization, plus Adam Keeney, who leads Corporate Development for us, we're examining holistically a range of possibilities centered on both research and development, so we can locate strategic assets that we feel can add to Biogen's growth story today and over the long-term. Having said that, I'd like to turn the call over to Mike at this point.
Mike McDonnell
executiveThanks, Priya. Morning, everybody. What I'll do is walk through a few highlights and add some color on how we performed financially in Q4 of 2023, and after that I'll give you some specifics behind the assumptions in our 2024 financial guidance. Just keep in mind that every financial comparison you're about to hear is against the fourth quarter of 2022. Revenue overall in Q4 2023 came to $2.4 billion. At actual currency that's down 6%, and at constant currency it's down 5%. Non-GAAP diluted earnings per share for the quarter was $2.95, which reflects a $0.35 negative hit from the closeout costs tied to ADUHELM that we recently disclosed. Taking a look at the full year 2023, we brought in $9.8 billion in total revenue. That represents a 3% decrease at actual currency and 1% at constant currency, which aligns with the low single-digit decline outlined in our most recent guidance. For the entire year 2023, non-GAAP diluted EPS was $14.72, which likewise falls within our latest guidance range of $14.50 to $15. In Q4, MS products generated $1.2 billion in revenue. That marks an 8% decline at actual currency and 6% at constant currency, with the drop primarily driven by competition, including generic TECFIDERA's impact. Now let me share a few brief updates regarding the MS business from Q4. Let's begin with TECFIDERA. In December, the European Commission withdrew the centralized marketing authorization for generic TECFIDERA in Europe. Through that move, the Commission affirmed that Biogen's marketing protection for TECFIDERA runs through February 2025. Until that point, TECFIDERA remains the only dimethyl fumarate MS therapy permitted for sale in the EU. Additionally, a TYSABRI biosimilar has entered the market in several European nations. We anticipate that additional biosimilar launches will occur across more European countries during the first half of 2024, and in the U.S. as well. Patents covering TYSABRI are held by Biogen, and we will continue our efforts to enforce our IP. Although VUMERITY experienced slight expansion during 2023, we're still facing downward pricing trends and a continuing contraction within the oral portion of the American market, and our expectation is that this will carry on through 2024. Turning now to news regarding our rare disease offerings, which include SPINRAZA, SKYCLARYS, and QALSODY. Revenue for Q4 came in at $472 million, representing a 3% increase using actual currency and a 6% gain on a constant currency basis. On the call for our third quarter, we noted that SPINRAZA shipments outside the United States benefited from the timing of deliveries in specific markets. That advantage during the earlier period created a drag on how the fourth quarter performed. Even though we expect SPINRAZA will deal with shipment timing effects once more during 2024, the drug's broader results remain a source of optimism for us. In Europe, where pricing pressure and competition are factors, SPINRAZA sales outside the U.S. took a slight hit during the fourth quarter. We remain the top player in the SMA market, and we continue to believe SPINRAZA can eventually return to growth. During its first full quarter under the Biogen umbrella, SKYCLARYS generated $56 million in revenue, and we're encouraged by the continued rise in patient numbers we've seen. Biosimilars revenue in the fourth quarter reached $188 million, up 8% in actual currency and 10% on a constant currency basis. We continue to review options for that business as we figure out how to maximize shareholder value from it. Within our anti-CD20 sales of $436 million, there was a $12 million operating loss related to how LUNSUMIO's economics work for us. In the fourth quarter, contract manufacturing, royalty and other revenue totaled $118 million, down significantly from a year earlier, largely due to batch timing — I'll explain more about that when I walk through our 2024 guidance in a moment. Now, a few things worth pointing out regarding fourth quarter expenses. Non-GAAP cost of sales represented 25% of total revenue in the fourth quarter, and that number includes $52 million in idle capacity charges. During Q4, our non-GAAP research and development spending decreased by $34 million. That figure still includes about $45 million associated with our share of the LEQEMBI partnership, along with approximately $60 million of closeout costs for ADUHELM. For non-GAAP SG&A, we saw a $44 million decline in the fourth quarter. This improvement was driven by cost savings initiatives totaling around $110 million, though it was partially offset by increased commercialization spending for the SKYCLARYS and LEQEMBI launches. Now, a brief note on our balance sheet. We ended the year holding $1 billion in cash and marketable securities, with $6.9 billion in debt, putting us at a net debt position of $5.9 billion. In Q4, we spent about $1.3 billion in cash to cover the final acquisition payment obligations from the Reata deal. On top of that, we repaid close to $350 million toward the $1 billion term loan we had arranged when we made this acquisition. One thing worth highlighting: within that $1.3 billion figure I just referenced, $393 million showed up in cash flow from operations as a one-time payment for equity-based compensation connected to the Reata transaction. Without that item, our full-year 2023 free cash flow, which came in at $1.3 billion, would have been roughly $1.7 billion. We anticipate continuing to produce robust cash flow throughout this year, and we look forward to getting a $437 million payment from Samsung during the early part of Q2 this year. Now I'll go over our guidance ranges and assumptions for the full year 2024; for the full year 2024, we expect non-GAAP diluted earnings per share between $15 and $16, which represents anticipated EPS growth of roughly 5% at the midpoint of that range versus 2023. Although total revenue is projected to fall by a low to mid-single-digit percentage, our core pharmaceutical revenue—that is, product revenue plus Biogen's 50% share of LEQEMBI revenue net of cost of sales and royalties—should be relatively flat in 2024 compared with 2023. The basis for this expectation is the revenue growth we anticipate from products launching during the year, which should about cancel out the decreases in our MS product revenue. Just like in prior years, for our U.S. MS business we anticipate that Q1 will be a seasonally softer quarter relative to Q4, and the reason for that is greater discounts and allowances plus certain channel dynamics. Contract manufacturing revenue is also anticipated to be considerably lower for all of 2024 versus 2023. Part of the reason is that we finished some batch commitments during 2023, tied to the 2020 divestiture of Hillerod, which sits in Denmark. That was where we had manufacturing operations. During 2023, roughly $320 million came from those batch commitments, and that revenue won't recur in 2024. A combination of factors should benefit cost of sales as a percentage of revenue in 2024: revenue growth tied to new product launches, the decline in contract manufacturing revenue, and lower idle capacity charges. Beyond that, we believe we can grow operating income by a low-double-digit percentage and expand operating margins by a mid-single-digit percentage compared with 2023. We expect the drivers to be an improved cost of sales as a percentage of revenue along with lower anticipated operating expenses resulting from our Fit for Growth initiative. On the Fit for Growth front, we continue to expect gross savings of roughly $1 billion by 2025, with $800 million remaining after reinvestments are accounted for. In 2023, we achieved savings of approximately $200 million. We're on track to secure another $200 million in 2024. That would get us to $400 million by year-end, which represents half of the total net savings, with the remaining portion coming in 2025. Looking at 2024, our 50% portion of SG&A costs for LEQEMBI — which, keep in mind, isn't included in our Fit for Growth calculations — and the shifting of resources for ADUHELM should approximately cancel each other out. When you put all of this together, we expect our total R&D and SG&A expenses for the full year 2024 to land at around $4.3 billion. Our other income and expense line, we expect, will keep acting as a headwind this year, because of lower interest income and higher interest expense stemming from the Reata acquisition. And so for 2024, we anticipate a better revenue profile, stronger margins, and a resumption of non-GAAP EPS growth. Returning to sustainable growth stays our top objective, and we stay dedicated to that objective and to building long-term value for our shareholders. And now I'll hand things back to Chris for some closing remarks.
Chris Viehbacher
executiveAppreciate that, Mike. So looking at this year, there are quite a few milestones all of us will be keeping a close eye on. As you're aware, a scientific advisory group concerning LEQEMBI is set for the first quarter, and if the CHMP outcome comes back positive, hopefully that paves the way for approval from the European Commission during the first half — later on within the first half of this year. With SKYCLARYS in the European Union, naturally, we just secured that, which we shared last night, and regarding European approval for QALSODY, a decision from the CHMP and the European Commission is anticipated in the first half. Regulatory submissions are on the horizon too, as you know, covering the subcutaneous formulation for LEQEMBI along with IV maintenance dosing, again for LEQEMBI. After that, as Priya mentioned, four data readouts are expected around mid-year across four programs. Like I noted before, my sense is we'll be devoting more and more of our time to the pipeline and to expanding it. So Chuck, I'll hand it back to you and see whether there are any questions.
Chuck Triano
executiveRight. Thanks, Chris. Katie, could you please open polling for questions? Thank you.
Marc Goodman
analystYes. Good morning. Could you take us through the subcu and the maintenance approvals? I suppose the timelines would be roughly around the end of the year, but please discuss what effect this has on the market. Let's assume Lilly is also on the market with a — they will receive approval shortly; so how do you think this will alter the dynamics and the uptake? And just give us a sense of that, please. And then also, perhaps you could just discuss the uptake in Japan that you anticipate? Thanks.
Chris Viehbacher
executiveYes. Thanks, Marc. Priya, do you want to just begin with the timelines, sort of? And I can cover the commercial side.
Priya Singhal
executiveYes, thanks for that, Marc. Overall, when we were at CTAD last year, we shared the results from our six-month dataset for the subcutaneous form. Our belief is that we've achieved bioequivalence with the IV version. Eisai gave us a recent update about the FDA meeting that's now on the calendar, which is meant to finalize the submission strategy. As of today, we still intend to file for the subcutaneous formulation by the close of March 2024. In addition, there's news about both the possibility of and the need for IV maintenance, and we're likewise aiming to submit that in Q1 2024. That's the current state of the plan. I'll pass it over to Chris now, who can address the dynamics plus the commercial side, including the 0.5 million figure.
Chris Viehbacher
executiveYeah, so Marc, the primary advantage of subcutaneous is really about making things easier for patients. And like we discussed before, eventually we're examining the AHEAD study, where it's possible that at some point we could secure an indication for patients in much earlier stages. We're also looking at maintenance, where patients ought to stay on treatment, assuming we receive approval, to stop plaque from coming back. So as we conduct these studies, the duration patients spend on the drug is anticipated to grow, and having a subcu version at any point in this disease could be pretty advantageous. Regarding how competitive we'll actually be against donanemab, I believe there will be several factors. We know physicians are extremely attuned to ARIA and safety concerns, and with LEQEMBI we have a safety profile that's considerably superior to donanemab's. There's something intriguing about the donanemab trial, which — their trial actually tracked patients until plaque levels dropped. So while Clarity assessed an endpoint for everyone at the same time point following 18 months, the endpoint for donanemab was variable when it came to time on the drug. And so it's not entirely clear what the stopping criteria are. And I think we need to find out what those are — if a PET scan is required, for example, that might be really burdensome; at this point we don't know if that will be the situation or not. But I think there will be a variety of factors through which we can compete against donanemab. And subcutaneous will be useful at some point. Clearly, if you consider this guidance, it appears donanemab is indicated — it's going to reach the market ahead of the subcutaneous formulation. So we're going to concentrate on several of those factors beyond subcutaneous and on competition. And afterward, once we see the label for Lily, once we see the label for the subcu, we'll build our commercial strategy to match.
Chuck Triano
executiveDo you want to comment on Japan?
Chris Viehbacher
executiveOh, Japan — right. Yes, my sense is that Eisai has essentially dedicated its entire field force to this, and not only the people assigned to LEQEMBI. Plus, you're dealing with a healthcare system run by the government. So I'd say a portion of the complications we face here in the United States — around reimbursement and the various parties involved — might be less of an issue there. That said, we do anticipate certain similar limitations when it comes to getting in to see neurologists and getting PET scans. In Japan, they'll likely rely considerably more on CSF markers and PET scans, yet my feeling is that adoption there could move more quickly than what we witnessed even in the United States, purely because of how that system works today. So we've only been at it since January, and we'll obviously provide another update during first quarter, though based on what our own colleagues in the field are telling us, physician response in Japan has been quite favorable.
Chuck Triano
executiveGreat. Thanks, Chris. Next question, please, operator.
Salveen Richter
analystMorning, and thanks for taking the question. I've got one about where things get stuck with the LEQEMBI launch. Could you address perhaps a couple of those points? First, what do you expect when it comes to Medicare Advantage reaching parity in coverage with traditional Medicare, and how long would that take? Second, can you give us an update on how patients are able to get in to see neurologists? Thank you.
Chris Viehbacher
executiveYeah, so I'll need to follow up on that — I haven't come across anything indicating Medicare Advantage differs from Medicare. Honestly, I've never posed that question, but I'll look into it. As far as I understand, though, they're the same. On the bottlenecks, I still — consider this: assuming the patient registry data is correct, and once more, we can't tap into it directly, but it points to roughly double the number of individuals in the registry compared with those receiving treatment. That tells us that beyond the hurdle of securing a neurologist appointment, there's also — once you're in the registry, your intent to prescribe is unmistakable, since with the registry, at minimum for CMS, you must detail how the diagnosis was in fact confirmed. By that stage, the patient has been triaged, you've completed either the PET scan or the CSF markers, and you're pursuing reimbursement. What we hear occasionally is that there's some difficulty simply booking that initial MRI, since when the infusion begins, that first MRI has to happen within the first two weeks. So nobody wants to start the infusion before having that MRI on the calendar. And with the MRI — there's no real capacity shortage as such, but you're after a particular date, and then the infusion has to be worked backward from it. So I think it's just that until everyone gets comfortable with this, handling all of that coordination, that strikes me as the — as one of the places where things back up.
Chuck Triano
executiveGreat. Thank you, Chris. Let's move to the next question please.
Umer Raffat
analystHello, everyone, and thank you for allowing me to ask. Today I wanted to bring up a somewhat different topic — your CD40 Phase 3 study in lupus. There are two parts to what I want to know. First, regarding the trial's size: it went from 450 participants down to 320. Could you address the difficulties in enrollment and whether those signal something favorable or unfavorable regarding efficacy? Second, on the primary endpoint, it contains three elements, yet it seems the FDA's guidance favors a single distinct index such as BILAG or SELENA-SLEDAI, among others. Have you reached agreement with the regulator on this? Thank you.
Priya Singhal
executiveThanks, Umer. I'll handle that question. To begin, we anticipate data from the initial Phase 3 around mid-2024. Should the outcome be positive, we anticipate needing another Phase 3 in order to produce the safety and efficacy data required to support a regulatory submission. A protocol amendment was made, and that involved collaborating quite closely with Biogen and UCB, examining the study's design, and weighing our obligation to carry out a well-constructed, informative trial against the wish to possibly speed up getting dapi to patients in need, assuming positive results. So we believe the study has suitable power, and we're continuing regulatory interactions and enabling a conversation about what comes next. Thus, in our view, yes — as things stand, it is set up to deliver a definitive readout regarding therapeutic potential. Yes.
Chuck Triano
executiveThanks, Priya. Let's go to our next question, please.
Evan Seigerman
analystHello, everyone. I really appreciate you taking my question. Chris, could you perhaps explain the reasoning behind allocating additional Biogen personnel to the LEQEMBI rollout, and also what has shifted or developed in the Eisai partnership that made you conclude more Biogen staff were required within the United States? Thanks.
Chris Viehbacher
executiveYes. Thank you, Evan. To be precise, we are putting in more from Biogen and more from Eisai as well. Twelve months back, Eisai's CEO and I discussed the LEQEMBI launch, and regarding the U.S., we simply went over how complicated the launch would be, and we have covered all of that already, and I will not put everyone through those details yet again, but our feeling was we truly wanted to be certain we grasped the go-to-market approach; alongside those neurology account specialists, there are MSLs, there are patient care navigators, there are individuals handling KMEs in the territory, and likely — for each NAS, there are another 2 or 3 individuals actually working in the field. And a tremendous amount of coordination is required. Even what an NAS does is fairly complicated since you must enter those offices, you must collaborate with them in helping them grasp the safety profile. You must assist them in grasping the care pathway. You must assist them in grasping reimbursement, not only for LEQEMBI, but reimbursement also applies to PET scans, MRIs, and the care itself. And last, there is what those in the field hold as a primary goal, why LEQEMBI? So we wanted to be certain we grasped all of that; and frankly, any time you engage in these copromotions, they demand a tremendous amount of coordination across the two companies; and our feeling was it would be easier if a single company went out initially. We were confident we knew precisely how the NAS role would function alongside the other supporting roles present in the field. And we also had to have a specific number of core IDNs prepared and signed up, since there is little benefit in raising the number of people in the field unless sufficient sites are activated and ready. So at this point we are over 6 months into the launch. I believe we feel quite at ease with how the NAS role functions. We grasp how much time passes between visiting a neurologist or an IDN and how much time will be needed for them to become activated, because, as I mentioned, you can deploy a tremendous amount of resource out there, but if you cannot pull the drug through, that is not a particularly efficient process. So that's the current state of things, and our confidence in that model is solid. Clearly, we've got to go out and bring in additional sites now. So we're examining this through geographic growth, and also, I'd say, even inside particular regions, maybe shrinking the territory footprint, since once these NASs are placed, they wind up devoting a considerable amount of time alongside the specialists. Thus, it was consistently the understanding between the two chief executives that as we expanded, Biogen would step in, yet both of us — what we're aiming for is maximum efficiency for the joint venture. And so our feeling was that early on, efficiency would be best served by having just a single company in the field. Now, we've clearly taken lessons from that, and that's precisely what gives us the assurance to deploy two companies into the field right away in Japan, as an example, since although markets differ, quite a few dynamics would be largely identical across those markets. So yes, it's a rise. Eisai is boosting their resources and so — and Biogen will be present too. And that may continue to change as time goes on. We'll be partners in this endeavor for many years ahead.
Chuck Triano
executiveRight, thanks, Chris. Now let's move to our next question, please.
Analyst
analystHey there, James here, filling in for Paul. Appreciate you fielding our question. I've got one more regarding lecanemab subcu, particularly among patients who haven't received prior treatment. I'm just curious whether you feel you've got sufficient data on the regulatory side, whether alignment has been reached with the regulators — both you and Eisai — and more specifically, do you have adequate safety information covering that treatment-naive group? Any insight you could offer would be terrific. Thanks.
Priya Singhal
executiveYes, so on the whole, this subject has come up in our conversations — Eisai and Biogen have talked it over with the FDA. To give some background, the plan involved adding a sub-study, a subcutaneous one, within the open-label extension of the Phase III CLARITY trial, and the treatment-naive lecanemab cohort numbered roughly 72 patients. Beyond that, an entire group of 322 further patients supplied safety and tolerability information. So the 72 patients serve as the basis for PK/PD and bioequivalents. However, a bigger data subset addresses the safety picture; so yes, talks continue, yet on the whole, these matters were reviewed with regulators before any of it began. Thank you.
Chuck Triano
executiveAppreciate it, Priya. Let's take the next one.
Phil Nadeau
analystMorning. My question concerns SKYCLARYS after the EU approval that came through last night. Chris pointed out how much the U.S. markets matter. Can you talk about what pace and path you anticipate for the SKYCLARYS rollout beyond the U.S. and Europe, and specifically, timing for availability in the major territories? Also, would you anticipate that pickup in those major territories will match the speed seen here in the United States? Thanks.
Chris Viehbacher
executiveI guess the launch has two parts. The first is early access programs, and the second is the formal launch. With this approval, for instance, we can now launch in Germany. That will be a formal launch; we still run an early access program, and any patients enrolled there will switch over to commercial patients. Keep in mind that in Europe, patients in early access programs are mostly expected to generate revenue. A separate program is already operating in France. We are also in negotiations to set up early access programs in two additional European countries, and discussions are underway about some early access programs in nations outside the EU. The early access program matters because, as everyone knows, securing pricing and reimbursement in Europe can take a while. That makes prediction somewhat difficult, since we need to grasp the cadence of these early access programs. My expectation, then, is that things will not move quite as quickly as they did in the U.S. That said, some suggest a warehousing effect could occur in Europe as well, but as I mentioned, and generally speaking, given the reimbursement timeline, plus the fact that early access programs cannot cover every country, uptake will be slower than in the U.S. That said, there are likely more patients per capita as well. Keep in mind this disease is tied to European descent. As a result, Friedreich's ataxia incidence is a bit higher in Europe than in the U.S. Latin America is the next big market opportunity, and we are filing in Brazil, and perhaps, Priya, you can update us on the regulatory time lines there.
Priya Singhal
executiveSure. What I can say is that we're genuinely working to speed up our regulatory submissions across Latin America — Brazil, Argentina. We haven't shared the timelines publicly yet, but our teams are moving very quickly, sitting down with regulators to pin down the routes that would get patients access as early as possible.
Chris Viehbacher
executiveOur best guess—getting exact figures isn't easy—is that somewhere between 2,000 and 4,000 patients are in Latin America. Therefore, drawing on what SPINRAZA has shown us, we anticipate that Latin America in particular will add a meaningful share to the revenue guidance we've provided. Since the genetics mean there are only a handful of patients in Asia, as you're aware, we have no plans to pursue filings or launches there.
Chuck Triano
executiveExcellent, thanks. Let's take the next question.
Michael Yee
analystAppreciate it; we had something about SKYCLARYS. Could you perhaps provide additional detail regarding what's driving things between 800 and 1,000 patients? And then how that path looks as we move into 2024 — I believe you said roughly 4,000 patients, but of that group, how many have actually been identified? From an expectations perspective, do you anticipate that growth will slow? Could you discuss a bit the complications in 2024 that you brought up? Thank you.
Chris Viehbacher
executiveYes. Thank you, Michael. Absolutely, growth will moderate. Keep in mind, when Reata still had this product, they held the approval. That was, I believe, during the first quarter. If my memory serves, it was February; however, a manufacturing specification problem prevented them from launching commercially. And that issue wasn't resolved until July. So basically, physicians and the market were aware that an approved product was on its way, and they simply awaited supply. So the warehousing effect, I'd argue, was larger than what typically happens with any rare disease drug. At this point we're back to the work of locating patients. I should mention that the Friedreich’'s Ataxia Research Alliance, also called FARA, is a remarkably effective patient association, and we're collaborating with them to assist in identifying patients. Diagnosing a patient accurately really does require a genetic test. However, that genetic test isn't widely sold and available. So we're needing to examine the situation and ensure that the provider of that test is able to make tests easily accessible. Beyond that, we're also handling the contracting to ensure that once patients have start forms, they can get on drug promptly; so I believe we'll return to a normal growth cadence for SKYCLARYS in the U.S. Another 20% this year isn't something we're necessarily going to achieve, but each month we're growing. And SKYCLARYS is definitely playing a major part in our return to growth in 2024.
Chuck Triano
executiveGreat. Thank you, Chris. Let's move to our next question, please.
Colin Bristow
analystMorning, and thanks for fielding these. One thing I'd like cleared up: a slide mentions that the subcu filing could come in the first half of '24, yet your remarks suggest it's still 24 — could you set that straight? Also, please spell out precisely what the FDA wants to see; when we last talked, I believe it was 12-month data. What part of that matters? Then, as a follow-up, regarding the three, four, five study, what timing or thresholds apply to any interim analysis? A — Priya Singhal I'll begin; regarding the subcutaneous, to put it plainly, Eisai stated only days ago during their earnings that our goal is to file by Q1 2024, meaning the close of this year's first quarter. Turning to AHEAD 3 to 45, this is essentially a platform — a group of platform trials using differing amyloid levels to define preclinical Alzheimer's disease; broadly speaking, A45 covers preclinical Alzheimer's disease with an enrollment goal of 1,000 patients, and those patients must show an amyloid level of 40 centiloids or above. Dosing occurs across three phases with varying doses — titration, induction and maintenance; in this trial, the outcome is a PAC 5, a preclinical composite for Alzheimer's disease that is sensitive to patients still in the preclinical phase. The A3 trial — its enrollment goal is roughly 400 million, and the preclinical amyloid cutoff falls between 20 and 40 centiloids. Once more, it uses a separate holding schedule of titration followed by maintenance. As for the primary endpoint in the A3 trial, that is really a biomarker endpoint. We haven't communicated exact time lines. These trials are very large. Eisai and Biogen, I think, are very pleased with how enrollment is going; and I think more will be communicated. An interim analysis is a possibility, and Eisai has addressed this, though no time line has been communicated yet.
Chuck Triano
executiveColin, a quick note about slide 28, right. The docs shows Q1, correct? Our wording says expected mid-year, if something sits around the middle of the year. So the confusion makes sense, since it says half one, half two, but the dots sit near the quarter's end there. So if you were checking — see whether a disconnect existed, there isn't one. What they've said is the end of March, which is what we're looking at here. So Priya…
Priya Singhal
executiveRegarding the second half of that question, let me just finish by saying that when it comes to the FDA, as I believe I said earlier, quite a few discussions have taken place. Eisai just brought up that another meeting has been added to the schedule. That approach will therefore be settled. With the 6-month data in front of us, what we observed gives us a lot of encouragement. In our view, the toughest bar—truly the largest obstacle—was achieving bioequivalence, and we think we have achieved it. So we will keep waiting for additional data. Even so, what we have seen up to now leaves us quite encouraged.
Chuck Triano
executiveAll right. Thank you, Priya. Let's go to our next questioner.
Chris Raymond
analystHey, thank you. I'd like to return to the Angelman program, perhaps, and get a clearer picture of what was said previously regarding it. Could you shed some light on the reasoning behind the choice to take part in development going forward? And clearly, there's a rival effort from Ultragenyx. I'm curious about your view on approvable endpoints. That has clearly remained a major unknown. And how do you believe this product, should it work, would stack up, plus any thoughts you might share regarding the competing set? Thanks.
Priya Singhal
executiveSure, sure. So to zoom out first, Ionis, our partner, is the one running this program, and under the terms of the contractual agreements, we hold the option to opt in, take the data we see midyear, and then choose whether we'd like to run a pivotal program — a pivotal study. That's the way it's structured. And then, backing up, I touched on it briefly during my opening remarks: this is a Phase Ib trial. In other words, it's a Phase I study being run in patients; it includes a multiple ascending dose portion lasting three months, then a long-term extension; so data will come to us. It spans various age groups and various doses. So what we'll get is a composite of data. And crucially, we'll be examining trends on EEG, since we know, as I mentioned, that these patients deal with the delta waves, the slowing. So that's something we'll be watching. plus clinical endpoints too. And to be very specific, there are a fair number of clinical endpoints. You've got the Bayley score, you've got the CGI, and you've got a Vineland. Every one of them will be examined. Turning outward to how we regard the competitive landscape: our feeling is that this program, as designed, sits in a well-positioned spot. Purely from an ASO standpoint, the backbone of the BIIB121 ASO, in our view, differs. That's 1 from the Ultragenyx ASO. Number two, our belief is that dosing might be required on a quarterly basis to truly observe the PK/PD impact we need — to make a difference in this disease. And we do have 3 monthly dosing in the LTE. So the MAD involves 2 doses administered 1 month apart. Then the third dose comes 2 months later, after which patients move into a 3-month dosing schedule. So we are — our feeling is that we'll have a data set available to examine and genuinely evaluate whether an adequate signal appears that would let us really move it into a Phase 3. And as for Roche discontinuing their program, our belief, once again, is that this is a separate product, and we believe a competitive advantage may be ours. In the end, naturally, we have to see the data.
Chuck Triano
executiveThank you, Priya. Let's move to the next question, please.
Mohit Bansal
analystExcellent. Many thanks for answering my question. Perhaps I could — if you would be willing to share a few thoughts about what you said earlier concerning SPINRAZA going back to growth. What's currently taking place in the marketplace? And what's your strategy for returning this product to growth? Thank you.
Chris Viehbacher
executiveCertainly. So, as you're aware, there's an oral treatment available from us. We also have a gene therapy, plus we have SPINRAZA, which is given intrathecally. So in the near term, one particularly significant piece of evidence involved showing how well SPINRAZA works after Zolgensma, since some people have felt that Zolgensma's effect fades with time; therefore, we're receiving what are termed switch packs, and regarding the oral treatment, there have occasionally seemed to be limits on its effectiveness tied to specific body weights. Thus we're actually able to target a larger adult population; our belief is that roughly 30% of SMA patients actually receive treatment. Obviously, pediatric patients get screened and are easily found. However, quite a few adult patients have the disease showing itself, yet diagnosis can sometimes prove challenging. And so we're returning to that rare disease task of searching for patients; though we think, in fact, we'll be the most app most suitable option for that group of patients; so that's one avenue for growth. And over a longer horizon, as you're aware, we have a high-dose SPINRAZA program being developed that might, should it succeed, result in just one intrathecal injection being needed; and that would bring about a huge change for patients when it comes to convenience and would render SPINRAZA even more competitive against the rest. Now that will still require a number of years, yet we do anticipate it reaching the market before SPINRAZA's patent expires.
Mike McDonnell
executiveRight, and let me jump in briefly on that point, Mohit. During — like we said in the remarks we prepared, you do tend to get some unevenness from one quarter to the next, especially when it comes to shipments outside the U.S. Still, taking 2023 as a whole, the U.S. actually posted slight growth, OUS saw a slight decrease, and on the whole we're getting back onto the slight growth path we've been aiming for, and we're happy with the way that franchise has settled down over time.
Chris Viehbacher
executiveYeah, it's a pattern where an oral therapy enters a market at some point, or gene therapy enters a market. When you hold 100% market share and a competitor arrives, mathematically speaking, you will give up market share. What we observe, though, is that churn happens for a year or two. After that, markets stabilize, and that's the moment when everyone starts paying attention to efficacy and patient populations. As I mentioned, we've managed so far to keep our leadership position in SMA even with competition around. And I believe that's how things will stay. Different patients will get different products, but the patient population remains large enough, and even with the switchbacks, we can locate reservoirs of growth.
Chuck Triano
executiveGreat, thanks. And operator, can we move to our last question, please.
Analyst
analystHey, everyone. Matt here, filling in for Jay. We really appreciate you letting us ask questions, and Jay says hello; so we were curious — I realize it's still early days, obviously, and the PPD launch is still a long way off, but do you have any metrics or signals that back up how confident you feel about the launch so far? And naturally, across the coming months to quarters, which metrics do you think will turn out to matter, and which ones might you intend to disclose? And perhaps your broader long-term objectives for that PPD launch, plus your overall interest in psychiatry, would be good to hear too. I really appreciate the question.
Chris Viehbacher
executiveSure. Thanks, stunt double. We — so a number of things strike me as pretty encouraging. First, our initial target has been psychiatrists who prescribe heavily in this area, along with OB-GYNs. And something we've been wondering about is whether OB-GYNs will truly be ready to write prescriptions. So one encouraging indicator is that they actually are. So we're seeing a fairly high share of prescriptions originating from them. Another has been, as I think I said before, that payers have genuinely been keen to make sure patients can get access, and I'm quite grateful to them. Take Medicaid, for instance, where 40% of births happen — they've acted very fast on this across a number of states. And some of the big — at least one of the big commercial insurers is moving far more quickly than we'd anticipated; so I think reimbursement is a key statistic; now, for my own part, I want to know how many patients are treatment-naive versus those who've already been on treatment. What's interesting is, is there also a warehousing effect at play? There's been a tremendous amount of media coverage. The product got approved in July. We couldn't launch because of the DEA inspection until the very end of 2023. So what we don't yet know is whether we're seeing a bolus of patients arrive because these are patients physicians have been tracking for a while who've been flagged as especially important to receive ZURZUVAE. So I think we'll need a bit more data on who the patients are and where they're coming from, but as I say, so far, we're running for the first month. I mean, we're definitely doing far better than what we'd expected; and we'll give you another update at Q1; we'll sit with Sage sometime in March to review the data and say, what do we see as some of the trends; but so far so good.
Chuck Triano
executiveExcellent. Thank you, Chris, and with that, we're bringing today's call to a close. We appreciate everyone taking part today.
Operator
operatorThat concludes today's call. We appreciate your participation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.